Monte Rosa Therapeutics, Inc.
GLUE
$16.86
$1.459.41%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1,112.27% | 2,990.57% | 14,889.38% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,112.27% | 2,990.57% | 14,889.38% | -- | -- |
| Cost of Revenue | 28.55% | 18.61% | 53.89% | 47.82% | 99.61% |
| Gross Profit | 158.86% | 158.53% | 154.76% | 51.23% | -70.18% |
| SG&A Expenses | 0.17% | -2.82% | 10.91% | 15.81% | -3.47% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.20% | 12.29% | 11.41% | 9.37% | 2.14% |
| Operating Income | 106.60% | 110.73% | 98.52% | 43.40% | 8.48% |
| Income Before Tax | 118.45% | 121.88% | 107.02% | 48.06% | 10.20% |
| Income Tax Expenses | 162.50% | 781.16% | 685.99% | 660.36% | 6.67% |
| Earnings from Continuing Operations | 117.54% | 118.53% | 104.55% | 46.29% | 10.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 117.54% | 118.53% | 104.55% | 46.29% | 10.15% |
| EBIT | 106.60% | 110.73% | 98.52% | 43.40% | 8.48% |
| EBITDA | 113.91% | 117.68% | 104.48% | 46.76% | 9.03% |
| EPS Basic | 113.97% | 113.11% | 100.71% | 59.01% | 31.92% |
| Normalized Basic EPS | 114.65% | 115.44% | 102.30% | 60.09% | 31.88% |
| EPS Diluted | 113.81% | 113.03% | 100.50% | 58.84% | 31.75% |
| Normalized Diluted EPS | 114.35% | 115.19% | 102.08% | 60.09% | 31.88% |
| Average Basic Shares Outstanding | 21.65% | 37.93% | 46.77% | 43.79% | 36.88% |
| Average Diluted Shares Outstanding | 21.95% | 38.27% | 47.15% | 43.79% | 36.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |